{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:05:55Z","timestamp":1790024755838,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40261-022-01163-5","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T14:03:32Z","timestamp":1653746612000},"page":"525-531","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1803-2046","authenticated-orcid":false,"given":"Matteo","family":"Megna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cataldo","family":"Patruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita","family":"Bongiorno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Gambardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Romita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Loconsole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Fabbrocini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,28]]},"reference":[{"key":"1163_CR1","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.057.","journal-title":"J Am Acad Dermatol"},{"key":"1163_CR2","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/ddg.14508","volume":"19","author":"A Nast","year":"2021","unstructured":"Nast A, Altenburg A, Augustin M, Boehncke WH, H\u00e4rle P, Klaus J, et al. German S3 guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm. Part 1: treatment goals and treatment recommendations. J Dtsch Dermatol Ges. 2021;19:934\u2013150. https:\/\/doi.org\/10.1111\/ddg.14508.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1163_CR3","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/jdv.14114","volume":"31","author":"P Gisondi","year":"2017","unstructured":"Gisondi P, Altomare G, Ayala F, Bardazzi F, Bianchi L, Chiricozzi A, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31:774\u201390. https:\/\/doi.org\/10.1111\/jdv.14114.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1163_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s13555-020-00475-8","volume":"11","author":"P Gisondi","year":"2021","unstructured":"Gisondi P, Talamonti M, Chiricozzi A, Piaserico S, Amerio P, Balato A, et al. Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations. Dermatol Ther. 2021;11:235\u201352. https:\/\/doi.org\/10.1007\/s13555-020-00475-8.","journal-title":"Dermatol Ther"},{"key":"1163_CR5","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s10067-018-4090-6","volume":"37","author":"M Megna","year":"2018","unstructured":"Megna M, Balato A, Napolitano M, Gallo L, Caso F, Costa L, et al. Psoriatic disease treatment nowadays: unmet needs among the \u201cjungle of biologic drugs and small molecules.\u201d Clin Rheumatol. 2018;37:1739\u201341. https:\/\/doi.org\/10.1007\/s10067-018-4090-6.","journal-title":"Clin Rheumatol"},{"key":"1163_CR6","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","volume":"58","author":"CR Holroyd","year":"2019","unstructured":"Holroyd CR, Seth R, Bukhari M, Malaviya A, Holmes C, Curtis E, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology. 2019;58:e3-42. https:\/\/doi.org\/10.1093\/rheumatology\/key208.","journal-title":"Rheumatology"},{"key":"1163_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/jdv.16926","volume":"35","author":"A Nast","year":"2021","unstructured":"Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Cs\u00f6rg\u00f6 Z, Boonen H, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris. Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35:281\u2013317. https:\/\/doi.org\/10.1111\/jdv.16926.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1163_CR8","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjd.19039","volume":"183","author":"CH Smith","year":"2020","unstructured":"Smith CH, Yiu ZZN, Bale T, Burden AD, Coates LC, Edwards W, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183:628\u201337. https:\/\/doi.org\/10.1111\/bjd.19039.","journal-title":"Br J Dermatol"},{"key":"1163_CR9","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.1177\/1203475418811347","volume":"23","author":"SM Poelman","year":"2019","unstructured":"Poelman SM, Keeling CP, Metelitsa AI. Practical guidelines for managing patients with psoriasis on biologics: an update. J Cutan Med Surg. 2019;23:3S-12S. https:\/\/doi.org\/10.1177\/1203475418811347.","journal-title":"J Cutan Med Surg"},{"key":"1163_CR10","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.jaad.2012.04.036","volume":"67","author":"A Abramson","year":"2012","unstructured":"Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. J Am Acad Dermatol. 2012;67:1349\u201361. https:\/\/doi.org\/10.1016\/j.jaad.2012.04.036.","journal-title":"J Am Acad Dermatol"},{"key":"1163_CR11","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s10067-010-1523-2","volume":"29","author":"MB Carroll","year":"2010","unstructured":"Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010;29:1021\u20139. https:\/\/doi.org\/10.1007\/s10067-010-1523-2.","journal-title":"Clin Rheumatol"},{"key":"1163_CR12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/BOR.0b013e328338f6df","volume":"22","author":"C Ferri","year":"2010","unstructured":"Ferri C, Govoni M, Calabrese L, The A. B, Cs of viral hepatitis in the biologic era. Curr Opin Rheumatol. 2010;22:443\u201350. https:\/\/doi.org\/10.1097\/BOR.0b013e328338f6df.","journal-title":"Curr Opin Rheumatol"},{"key":"1163_CR13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.4254\/wjh.v7.i3.344","volume":"7","author":"F De Nard","year":"2015","unstructured":"De Nard F, Todoerti M, Grosso V, Monti S, Breda S, Rossi S, et al. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: extending perspective from old to newer drugs. World J Hepatol. 2015;7:344\u201361. https:\/\/doi.org\/10.4254\/wjh.v7.i3.344.","journal-title":"World J Hepatol"},{"key":"1163_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jaad.2017.01.037","volume":"77","author":"I Snast","year":"2017","unstructured":"Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature. J Am Acad Dermatol. 2017;77:88-97.e5. https:\/\/doi.org\/10.1016\/j.jaad.2017.01.037.","journal-title":"J Am Acad Dermatol"},{"key":"1163_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jaad.2019.12.001","volume":"85","author":"HY Chiu","year":"2021","unstructured":"Chiu HY, Chiu YM, Chang Liao NF, Chi CC, Tsai TF, Hsieh CY, et al. Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study. J Am Acad Dermatol. 2021;85:337\u201344. https:\/\/doi.org\/10.1016\/j.jaad.2019.12.001.","journal-title":"J Am Acad Dermatol"},{"key":"1163_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/PTT.S108209","volume":"7","author":"MV Cannizzaro","year":"2017","unstructured":"Cannizzaro MV, Franceschini C, Esposito M, Bianchi L, Giunta A. Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management. Psoriasis. 2017;7:35\u201340. https:\/\/doi.org\/10.2147\/PTT.S108209.","journal-title":"Psoriasis."},{"key":"1163_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80:43\u201353. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.056.","journal-title":"J Am Acad Dermatol"},{"key":"1163_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80:27\u201340. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.057.","journal-title":"J Am Acad Dermatol"},{"key":"1163_CR19","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2340\/00015555-2989","volume":"98","author":"HY Chiu","year":"2018","unstructured":"Chiu HY, Hui RC, Huang YH, Huang RY, Chen KL, Tsai YC, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study. Acta Derm Venereol. 2018;98:829\u201334. https:\/\/doi.org\/10.2340\/00015555-2989.","journal-title":"Acta Derm Venereol"},{"key":"1163_CR20","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/ijd.15217","volume":"60","author":"M Megna","year":"2021","unstructured":"Megna M, Ferrillo M, Ruggiero A, Cinelli E, Gallo L, Fabbrocini G. QuantiFERON TB-gold conversion rate among psoriasis patients under biologics: a 9-year retrospective study. Int J Dermatol. 2021;60:352\u20137. https:\/\/doi.org\/10.1111\/ijd.15217.","journal-title":"Int J Dermatol"},{"key":"1163_CR21","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.3748\/wjg.v17.i34.3881","volume":"17","author":"CM Mastroianni","year":"2011","unstructured":"Mastroianni CM, Lichtner M, Citton R, Del Borgo C, Rago A, Martini H, et al. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol. 2011;17:3881\u20137. https:\/\/doi.org\/10.3748\/wjg.v17.i34.3881.","journal-title":"World J Gastroenterol"},{"key":"1163_CR22","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1080\/14740338.2016.1221923","volume":"15","author":"A Blauvelt","year":"2016","unstructured":"Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf. 2016;15:1413\u201320. https:\/\/doi.org\/10.1080\/14740338.2016.1221923.","journal-title":"Expert Opin Drug Saf"},{"key":"1163_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/2040622317738910","volume":"9","author":"J Frieder","year":"2018","unstructured":"Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018;9:5\u201321. https:\/\/doi.org\/10.1177\/2040622317738910.","journal-title":"Ther Adv Chronic Dis."},{"key":"1163_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/imm.12142","volume":"141","author":"BW Kirkham","year":"2014","unstructured":"Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141:133\u201342. https:\/\/doi.org\/10.1111\/imm.12142.","journal-title":"Immunology"},{"key":"1163_CR25","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.3892\/mmr.2017.7044","volume":"16","author":"S Bao","year":"2017","unstructured":"Bao S, Zheng J, Shi G. The role of T helper 17 cells in the pathogenesis of hepatitis B virus-related liver cirrhosis (review). Mol Med Rep. 2017;16:3713\u20139. https:\/\/doi.org\/10.3892\/mmr.2017.7044.","journal-title":"Mol Med Rep"},{"key":"1163_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.imlet.2012.12.001","volume":"149","author":"B Yang","year":"2013","unstructured":"Yang B, Wang Y, Zhao C, Yan W, Che H, Shen C, et al. Increased Th17 cells and interleukin-17 contribute to immune activation and disease aggravation in patients with chronic hepatitis B virus infection. Immunol Lett. 2013;149:41\u20139. https:\/\/doi.org\/10.1016\/j.imlet.2012.12.001.","journal-title":"Immunol Lett"},{"key":"1163_CR27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s40257-015-0143-7","volume":"16","author":"KP Garnock-Jones","year":"2015","unstructured":"Garnock-Jones KP. Secukinumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol. 2015;16:323\u201330. https:\/\/doi.org\/10.1007\/s40257-015-0143-7.","journal-title":"Am J Clin Dermatol"},{"key":"1163_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21:111. https:\/\/doi.org\/10.1186\/s13075-019-1882-2.","journal-title":"Arthritis Res Ther"},{"key":"1163_CR29","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med. 2014;371:326\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1314258.","journal-title":"N Engl J Med"},{"key":"1163_CR30","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","volume":"56","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Mease PJ, Ritchlin CT, Rahman P, Gottlieb AB, Kirkham B, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford). 2017;56:1993\u20132003. https:\/\/doi.org\/10.1093\/rheumatology\/kex301.","journal-title":"Rheumatology (Oxford)"},{"key":"1163_CR31","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/jdv.16124","volume":"34","author":"K Reich","year":"2020","unstructured":"Reich K, Warren RB, Coates LC, Di Comite G. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol. 2020;34:1161\u201373. https:\/\/doi.org\/10.1111\/jdv.16124.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1163_CR32","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","volume":"73","author":"D Thaci","year":"2015","unstructured":"Thaci D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2015.05.013.","journal-title":"J Am Acad Dermatol"},{"key":"1163_CR33","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.jaad.2019.04.045","volume":"81","author":"D Thaci","year":"2019","unstructured":"Thaci D, Puig L, Reich K, Tsai TF, Tyring S, Kingo K, et al. Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: results from the CLEAR study. J Am Acad Dermatol. 2019;81:1405\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2019.04.045.","journal-title":"J Am Acad Dermatol"},{"key":"1163_CR34","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1111\/jdv.14608","volume":"32","author":"SL Bevans","year":"2018","unstructured":"Bevans SL, Mayo TT, Elewski BE. Safety of secukinumab in hepatitis B virus. J Eur Acad Dermatol Venereol. 2018;32:e120\u20131. https:\/\/doi.org\/10.1111\/jdv.14608.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1163_CR35","doi-asserted-by":"crossref","unstructured":"Feaster B, Cline A, Feldman SR. Secukinumab for psoriasis in a patient with hepatitis B. Dermatol Online J. 2018;24:13030\/qt58t2f0jh.","DOI":"10.5070\/D3249041421"},{"key":"1163_CR36","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1097\/CM9.0000000000001801","volume":"134","author":"RH Hou","year":"2021","unstructured":"Hou RH, Wen XT, Wang Q, Wang L. Using secukinumab in a patient with endplate inflammation complicated by hepatitis B virus infection. Chin Med J. 2021;134:2644\u20136. https:\/\/doi.org\/10.1097\/CM9.0000000000001801.","journal-title":"Chin Med J"},{"issue":"sup2","key":"1163_CR37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/09546634.2018.1543843","volume":"29","author":"C Lasagni","year":"2018","unstructured":"Lasagni C, Bigi L, Conti A, Pellacani G. Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies. J Dermatol Treat. 2018;29(sup2):5\u20138. https:\/\/doi.org\/10.1080\/09546634.2018.1543843.","journal-title":"J Dermatol Treat"},{"key":"1163_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/ejhpharm-2017-001212","volume":"25","author":"V Martinez-Santana","year":"2018","unstructured":"Martinez-Santana V, Rodriguez-Murphy E, Smithson A, Miserachs-Aranda N, Del R\u00edo-Gil R, Torre-Llover\u00e1s I. Efficacy and safety of direct-acting antiviral agents when combined with secukinumab. Eur J Hosp Pharm. 2018;25:53\u20136. https:\/\/doi.org\/10.1136\/ejhpharm-2017-001212.","journal-title":"Eur J Hosp Pharm"},{"key":"1163_CR39","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ad.2019.02.022","volume":"111","author":"LM Moneva-Leniz","year":"2020","unstructured":"Moneva-Leniz LM, Sahuquillo-Torralba A, Vila-Payeras A, Mateu-Puchades A. Risk of hepatitis B virus reactivation in patients on secukinumab for psoriasis: a series of 4 cases. Actas Dermosifiliogr. 2020;111:613\u20134. https:\/\/doi.org\/10.1016\/j.ad.2019.02.022.","journal-title":"Actas Dermosifiliogr"},{"key":"1163_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12601","volume":"31","author":"F Peccerillo","year":"2018","unstructured":"Peccerillo F, Odorici G, Pellacani G, Conti A. Secukinumab: a positive outcome in a patient with severe psoriasis and HBV-HCV co-infection. Dermatol Ther. 2018;31: e12601. https:\/\/doi.org\/10.1111\/dth.12601.","journal-title":"Dermatol Ther"},{"key":"1163_CR41","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s13555-020-00373-z","volume":"10","author":"JJ Wu","year":"2020","unstructured":"Wu JJ, Merola JF, Feldman SR, Menter A, Lebwohl M. Treatment of psoriasis with secukinumab in challenging patient scenarios: a review of the available evidence. Dermatol Ther. 2020;10:351\u201364. https:\/\/doi.org\/10.1007\/s13555-020-00373-z.","journal-title":"Dermatol Ther"},{"key":"1163_CR42","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1684\/ejd.2016.2939","volume":"27","author":"S Yanagihara","year":"2017","unstructured":"Yanagihara S, Sugita K, Yoshida Y, Tsuruta D, Yamamoto O. Psoriasis vulgaris in a hepatitis B virus carrier successfully treated with secukinumab and entecavir combination therapy. Eur J Dermatol. 2017;27:185\u20136. https:\/\/doi.org\/10.1684\/ejd.2016.2939.","journal-title":"Eur J Dermatol"},{"key":"1163_CR43","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3899\/jrheum.190116","volume":"47","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Gladman DD, McInnes IB, Spindeldreher S, Martin R, Pricop L, et al. Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis. J Rheumatol. 2020;47:539\u201347. https:\/\/doi.org\/10.3899\/jrheum.190116.","journal-title":"J Rheumatol"},{"key":"1163_CR44","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1111\/jdv.15637","volume":"33","author":"K Reich","year":"2019","unstructured":"Reich K, Blauvelt A, Armstrong A, Langley RG, de Vera A, Kolbinger F, et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. J Eur Acad Dermatol Venereol. 2019;33:1733\u201341. https:\/\/doi.org\/10.1111\/jdv.15637.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1163_CR45","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13555-018-0220-y","volume":"8","author":"S Spindeldreher","year":"2018","unstructured":"Spindeldreher S, Maillere B, Correia E, Tenon M, Karle A, Jarvis P, et al. Secukinumab demonstrates significantly lower immunogenicity potential compared to ixekizumab. Dermatol Ther. 2018;8:57\u201368. https:\/\/doi.org\/10.1007\/s13555-018-0220-y.","journal-title":"Dermatol Ther"},{"key":"1163_CR46","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31:299\u2013316. https:\/\/doi.org\/10.1007\/s40259-017-0231-8.","journal-title":"BioDrugs"},{"key":"1163_CR47","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40257-019-00457-3","volume":"20","author":"S Piaserico","year":"2019","unstructured":"Piaserico S, Messina F, Russo FP. Managing psoriasis in patients with HBV or HCV infection: practical considerations. Am J Clin Dermatol. 2019;20:829\u201345. https:\/\/doi.org\/10.1007\/s40257-019-00457-3.","journal-title":"Am J Clin Dermatol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01163-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01163-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01163-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T11:23:37Z","timestamp":1654946617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01163-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,28]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1163"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01163-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,28]]},"assertion":[{"value":"8 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Napoli Federico II within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Matteo Megna has acted as a speaker or consultant for Abbvie, Amgen, Eli Lilly, Leo Pharma, Janssen, Novartis, and UCB. Gabriella Fabbrocini has acted as a speaker or consultant for Abbvie, Almirall, Amgen, Eli Lilly, Leo Pharma, Janssen, Novartis, Sanofi, and UCB. Cataldo Patruno has acted as an advisor, consultant, speaker, and\/or investigator for AbbVie, Amgen, Eli Lilly, Leo Pharma, Novartis, Pfizer, Pierre Fabre, and Sanofi. Claudio Guarneri has received consultation fees and\/or grants for research projects and advisory panels and for giving educational lectures from Wyeth-Pfizer, Abbott Immunology-Abbvie, Janssen-Cilag, Novartis, LEO-Pharma, Ely-Lilly, Celgene, Merck-Serono, Sanofi-Aventis, Amgen, and Almirall. The other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures related to this work adhered to the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, and its amendments. This study received approval from the local ethics committee or institutional review board at each participating institution.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from the patients at the time of being prescribed secukinumab. Additional consent for participation in the study was not required and only anonymized data were used in the analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors made a significant contribution to the work reported, whether in the conception, study design, execution, acquisition of data, analysis, and interpretation, or in all these areas; took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}